FDA 授予 Pacira 治疗膝骨关节炎的基因疗法 PCRX-201 RMAT 资格。 FDA grants RMAT designation to Pacira's gene therapy PCRX-201 for knee osteoarthritis.

Pacira BioSciences 的基因治疗候选产品 PCRX-201 已获得 FDA 的膝骨关节炎 RMAT 指定。 Pacira BioSciences' gene therapy product candidate, PCRX-201, has received RMAT designation from the FDA for osteoarthritis of the knee. PCRX-201 是第一个获得骨关节炎指定的基因治疗产品，它编码 IL-1Ra，一种阻止炎症的细胞因子抑制剂。 The first gene therapy product to receive this designation for osteoarthritis, PCRX-201 codes for IL-1Ra, a cytokine inhibitor that blocks inflammation. RMAT 指定提供了与 FDA 的早期互动，以实现高效的药物开发、潜在的加速批准和优先审查。 The RMAT designation offers early interactions with the FDA for efficient drug development, potential accelerated approval, and priority review.